Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 12, 2004, Pages 741-744

  Markman, Maurie ^a,b   Markman, Jon ^b   Webster, Kenneth ^b   Zanotti, Kristine ^b   Kulp, Barbara ^b   Peterson, Gertrude ^b   Belinson, Jerome ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Carboplatin; Chemotherapy; Ovarian cancer; Thrombocytopenia

Indexed keywords

CARBOPLATIN; CISPLATIN; IRINOTECAN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CLINICAL EXAMINATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; EXPERIENCE; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; OUTPATIENT DEPARTMENT; OVARY CANCER; PERITONEAL CAVITY; PERITONEUM CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

ADULT; AGED; CARBOPLATIN; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 12444323594     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0598-z     Document Type: Review

References (16)

1. Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, Parazzini F (2001) Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81:3-9
2. Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M, Johnston M (2002) Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage III, III, or IV epithelial ovarian cancer. Gynecol Oncol 85:71-80
3. Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E, Spriggs DR (2002) Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 20:1238-1247
4. Goldberg GL, Gibbon DG, Smith HO, DeVictoria C, Runowicz CD, Burns ER (1994) Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. J Clin Oncol 12:2317-2320
5. Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepherd J (1998) Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol 16:2426-2434
6. Gronlund B, Hogdall C, Hansen HH, Engelholm SA (2001) Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 83:128-134
7. Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, Nielsen K, Sandberg E, Stroeyer I (1997) Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 15:193-198
8. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528
9. Joly F, Heron JF, Kerbrat P, Chauvergne J, Rios M, Mayer F, Chinet-Charrot P, Goupil A, Lebrun-Jezekova D, Vennin D, Lhomme C, Mace-Lesec'h J, Crouet H (2000) High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecol Oncol 78:361-368
10. Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. Oncologist 5:26-35
11. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1997) Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol 65:434-436
12. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599
13. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200
14. Rose PG, Fusco N, Fluellen L, Rodriguez M (1998) Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 16:1494-1497
15. The ICON and AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106
16. The International Collaborative Ovarian Neoplasm (ICON) Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505-515